Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Alaris Medical

This article was originally published in The Gray Sheet

Executive Summary

Alaris Medical: San Diego-based infusion products firm says it is "proceeding with negotiations" regarding a dispute over its maquiladora manufacturing facilities in Tijuana, Mexico. The dispute is with Cal Pacifico, a Newport Beach, California contractor of maquiladora manufacturing services through which Alaris manufactures its products at two Tijuana plants under a "shelter" arrangement. Alaris says it notified Cal Pacifico in April that it would terminate the shelter program Aug. 1 and would take over its own manufacturing operation in Mexico. On June 11, five days after Alaris hired workers at the two plants, Cal Pacifico expelled all Alaris personnel from the facilities, thereby halting production. Alaris says it is ramping up manufacturing activities at its sites in San Diego, North Carolina, and Europe to address the shut down in Mexican operations and is "working diligently with Mexican authorities" to resume manufacturing in that country. The firm notes that it "does not anticipate that the dispute will have an impact on customers or results of its operations for the second quarter"...

You may also be interested in...

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts